Real-world cost-effectiveness: Lower cost of treating patients to glycemic goal with liraglutide versus exenatide

Advances in Therapy

Volumn 31, Issue 2, 2014, Pages 202-216

  DeKoven, Mitch ^a   Lee, Won Chan ^a   Bouchard, Jonathan ^b   Massoudi, Marjan ^b   Langer, Jakob ^b  

^a IQVIA   (United States)

^b NOVO NORDISK INC   (United States)

Author keywords

Cost effectiveness; Endocrinology; Exenatide; Glycated hemoglobin A1C goal attainment; Glycemic control; Liraglutide; Type 2 diabetes

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; LIRAGLUTIDE;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACEUTICAL CARE;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COSTS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOMS; YOUNG ADULT;

EID: 84899128195     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0098-8     Document Type: Article

References (22)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033-46.
2. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-59.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
4. Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Syst Rev. 2011;10:CD006423.
5. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.
6. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-81.
7. Nisal K, Kela R, Khunti K, Davies MJ. Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus. BMC Med. 2012;10:152.
8. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447-56.
9. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
10. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381:117-24.
11. Fakhoury WKH, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology. 2010;86:44-57.
12. Centers for Medicare and Medicaid Services. Innovation models. http://innovation.cms.gov/initiatives/index.html#views=models. Accessed October 9, 2012.
13. Goldsmith J. Accountable care organizations: the case for flexible partnerships between health plans and providers. Health Aff. 2011;30:32-40.
14. Stolar MW, Hoogwerf BJ, Boyle PJ, Gorshow SM, Wales DO. Managing type 2 diabetes: going beyond glycemic control. J Manag Care Pharm. 2008;14:S2-19.
15. Pelletier EM, Pawaskar M, Smith PJ, Best JH, Chapman RH. Economic outcomes of exenatide versus liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis. J Med Econ. 2012;15:1039-50.
16. Lee WC, Conner C, Hammer M. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Clin Ther. 2010;32:1756-67.
17. Evans M, McEwan P, O'Shea R, George L. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice. Diabetes Therapy. 2013;4:27-40.
18. Valentine WJ, Palmer AJ, Lammert M, Langer J, Brandle M. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clin Ther. 2011;33:1698-712.
19. Langer J, Hunt B, Valentine WJ. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. J Manag Care Pharm. 2013;19:237-46.
20. Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65:397-407.
21. Brown DW, Anda RF, Felitti VJ. Self-reported information and pharmacy claims were comparable for lipid-lowering medication exposure. J Clin Epidemiol. 2007;60:525-9. (Pubitemid 46529144)
22. Richardson K, Kenny RA, Peklar J, Bennett K. Agreement between patient interview data on prescription medication use and pharmacy records in those aged older than 50 years varied by therapeutic group and reporting of indicated health conditions. J Clin Epidemiol. 2013;66:1308-16.